Somewhat Positive News Coverage Somewhat Unlikely to Affect uniQure N.V. (NASDAQ:QURE) Stock Price
Media coverage about uniQure N.V. (NASDAQ:QURE) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. uniQure N.V. earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media headlines about the biotechnology company an impact score of 46.1094565029551 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern’s rankings:
- What Kind of Picture Are the Technicals Painting For Uniqure NV (QURE)? – Stock Press Daily (stockpressdaily.com)
- uniQure N.V. – Ordinary Shares (NASDAQ:QURE) Experiences Light … – Modern Readers (modernreaders.com)
- uniQure Announces Leadership Team Appointments and … – GlobeNewswire (press release) (globenewswire.com)
- uniQure N.V. (NASDAQ:QURE) Expected to Post Quarterly Sales of $2.92 Million (americanbankingnews.com)
- Uniqure NV (QURE) Shares Needle Moving 2.35% – Evergreen Caller (evergreencaller.com)
uniQure N.V. (QURE) opened at 8.09 on Tuesday. The stock’s market capitalization is $205.83 million. uniQure N.V. has a 12-month low of $4.72 and a 12-month high of $9.72. The stock’s 50 day moving average price is $6.63 and its 200-day moving average price is $5.94.
uniQure N.V. (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($0.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.64) by $0.16. The business had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $4.20 million. uniQure N.V. had a negative net margin of 223.38% and a negative return on equity of 103.26%. Analysts expect that uniQure N.V. will post ($3.51) earnings per share for the current year.
Several analysts have issued reports on the company. ValuEngine upgraded uniQure N.V. from a “sell” rating to a “hold” rating in a report on Monday, July 24th. Chardan Capital set a $13.00 price target on uniQure N.V. and gave the stock a “buy” rating in a report on Sunday, July 23rd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and set a $17.00 price target on shares of uniQure N.V. in a report on Friday, June 30th. Cowen and Company reiterated a “buy” rating on shares of uniQure N.V. in a report on Wednesday, May 24th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $8.00 price target on shares of uniQure N.V. in a report on Wednesday, April 12th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $14.61.
In other news, insider Harald Petry sold 49,300 shares of uniQure N.V. stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $6.02, for a total value of $296,786.00. Following the completion of the sale, the insider now owns 27,753 shares of the company’s stock, valued at $167,073.06. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In the last ninety days, insiders sold 173,460 shares of company stock valued at $1,042,986. Company insiders own 0.64% of the company’s stock.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.